This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
02/08/16 - 9:55:03 AM ET (BATS BZX Real-time Price)
Div Yield: --
MACK Day's Range
MACK 52 Week Range
MACK Business Summary
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States.View MACK
Merrimack Pharmaceuticals Inc - MACK - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Merrimack Pharmaceuticals Inc as a
Sell with a ratings score of D-.
Report Snippet: We rate MERRIMACK PHARMACEUTICALS (MACK) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.